CD8A and neoplasm: On the one hand, dMMR CRC harbors a high tumor mutational burden (TMB) that leads to high mutation-associated neoantigen load, higher CD8+ cytotoxic T and Th1 helper cells infiltration [15], and high levels of human leukocyte antigen (HLA) proteins.